CLINICAL ROLE -
Ryan Haumschild, PharmD, MS, MBA, provides insights surrounding the utilization of PARP inhibitors and clinical pathways in ovarian cancer treatment.
EP. 1: The Involvement of PARP Inhibitors in the Treatment Landscape for Ovarian Cancer
Ryan Haumschild, PharmD, MS, MBA, opens a discussion surrounding the use of PARP inhibitors within the treatment landscape for ovarian cancer.
EP. 2: Safety and Dosage Considerations for PARP Inhibitors
Dr Haumschild explores considerations for safe and appropriate dosing for patients receiving PARP inhibitor therapy.
EP. 3: Multidisciplinary Collaboration Optimizing PARP Inhibitor Regimens
The significance of multidisciplinary teams in ovarian cancer treatment is highlighted.
EP. 4: Utilizing Clinical Pathways to Guide Treatment in Patients with Ovarian Cancer
Dr Haumschild discusses the substantial impact of clinical pathways in the treatment of ovarian cancer.
EP. 5: Cost Considerations for Treatment Involving a PARP Inhibitor
Dr Haumschild navigates financial considerations associated with treatment of ovarian cancer.
EP. 6: Examining Safety Profiles in Patients with Ovarian Cancer
Quality of life and safety profiles are discussed by Ryan Haumschild, PharmD, MS, MBA.
EP. 7: Benefits and Limitations in Current Treatment Pathways for Ovarian Cancer
A medical expert navigates clinical pathway considerations in the treatment of ovarian cancer.
EP. 8: Unmet Needs in the Implementation of Clinical Pathways in Ovarian Cancer
In his closing thoughts, Dr Haumschild discusses unmet needs in the treatment landscape for ovarian cancer.
2 Clarke Drive Cranbury, NJ 08512